Meta-analysis of memantine: Summary and commentary on the Cochrane Collaboration's systematic review

Alzheimer's and Dementia

Volumn 1, Issue 1, 2005, Pages 67-71

  McShane, Rupert ^a   Schneider, Lon S ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; DISEASE SEVERITY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; META ANALYSIS; MULTIINFARCT DEMENTIA; NATIONAL HEALTH SERVICE; PEER REVIEW; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RESTLESSNESS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 33644813064     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2005.06.025     Document Type: Article

References (19)

1. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. Available at http://www.thecochranelibrary.com. Accessed 12 July 2005.
2. Areosa Sastre A, McShane R, Sherriff F. Memantine for dementia. The Cochrane Database of Systematic Reviews 2005, Issue 3. July 2005. Art. No.: CD003154.
3. National Institute for Clinical Excellence. Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease (including a review of existing guidance no. 19). Available at http://www.nice.org.uk/page.aspx?o=104058. Accessed 12 July 2005.
4. Office of the New York State Attorney General. Forest labs to establish clinical trials registry (press release). September 7, 2004. Available at http://www.oag.state.ny.us/press/2004/sep/sep7b_04.html. Accessed May 20, 2005
5. Study No. MEM-MD-01, a randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer's type. Available at www.forestclinicaltrials.com. Accessed May 5, 2005.
6. Peskind ER, Potkin SG, Pomara N, Ott BR, McDonald S, Gergel I. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. In: CINP Congress, Paris. June 2-24. 2004.
7. Forest Laboratories, Inc. Namenda (memantine HCl) mild to moderate Alzheimer's disease studies reported today Forest Laboratories to seek approval for mild to moderate indication by mid-year (press release). January 7, 2004. Available at http://ir.frx.com/phoenix.zhtml?c=83198&p=irol-newsArticle& ID=482107amp;highlight = Accessed October 5, 2004.
8. Forest Laboratories, Inc. Combined therapy of memantine and acetylcholinesterase inhibitors for the treatment of mild to moderate Alzheimer's disease did not demonstrate statistically significant effects on cognitive or global outcome compared to placebo/ acetylcholinesterase treatment (press release). 19th June 2003. Available at http://ir.frx.com/phoenix.zhtml?c=83198&p=irol- newsArticle&ID=423766&highlight = Accessed October 5, 2004.
9. B. Reisberg R. Doody A. Stöffler F. Schimitt S. Ferris H.J. Möbius Memantine Study group Memantine in moderate to severe Alzheimer's disease N Engl Med 348 2003 1333-1341
10. P. Tariot M. Farlow T. Grossberg S. Graham S. McDonald I. Gergel memantine study group Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial JAMA 291 2004 317-324
11. J.M. Orgogozo A.S. Rigaud A. Stöffler H.J. Möbius F. Forette Efficacy and safety of memantine in patients with mild to moderate vascular dementia A randomized, placebo-controlled trial (MMM300 Trial Group) Stroke 33 2002 1834-1839
12. G. Wilcock H.J. Möbius A. Stöffler MM 500 group A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia Int Clin Psychopharmacol 17 2002 297-305
13. B. Winblad N. Poritis Memantine in severe dementia results of the 9M-BEST study (Benefit and efficacy in severely demented patients during treatment with memantine) Int J Geriatr Psychiatry 14 1999 135-146
14. K. Ditzler Efficacy and tolerability of memantine in patients with dementia syndrome Arzneimittelforschung 41 1991 773-780
15. R. Gortelmeyer H. Erbler Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study Arzneimittelforschung 42 1992 904-913
16. M. Pantev R. Ritter R. Gortelmeyer Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment Zeitschrift fuer Gerontopsychologie und Psychiatrie 6 1993 103-117
17. P.N. Tariot R.S. Doody E.R. Peskind B. Winblad A. Stoeffler H.J. Moebius et. al. Memantine treatment for mild to severe Alzheimer's disease clinical trials summary J Eur Coll Neuropsychopharmacol 14 Supp 3 2004 S327 P.4.012. 17th European College Neuropsychopharmacology conference 11th October
18. H. Feldman S. Gauthier J. Hecker B. Vellas P. Subbiah E. Whalen Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613-620
19. S. Gauthier Y. Wirth H.J. Möbius Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies Int J Geriatr Psychiatry 20 2005 459-464